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Selenium has been implicated in cancer prevention,
but the mechanism and possible involvement of seleno-
proteins in this process are not understood. To elucidate
whether the 15-kDa selenoprotein may play a role in
cancer etiology, the complete sequence of the human
15-kDa protein gene was determined, and various char-
acteristics associated with expression of the protein
were examined in normal and malignant cells and tis-
sues. The 51-kilobase pair gene for the 15-kDa selenopro-
tein consisted of five exons and four introns and was
localized on chromosome 1p31, a genetic locus com-
monly mutated or deleted in human cancers. Two stem-
loop structures resembling selenocysteine insertion se-
quence elements were identified in the 3*-untranslated
region of the gene, and only one of these was functional.
Two alleles in the human 15-kDa protein gene were
identified that differed by two single nucleotide poly-
morphic sites that occurred within the selenocysteine
insertion sequence-like structures. These 3*-untrans-
lated region polymorphisms resulted in changes in sel-
enocysteine incorporation into protein and responded
differently to selenium supplementation. Human and
mouse 15-kDa selenoprotein genes manifested the high-
est level of expression in prostate, liver, kidney, testis,
and brain, and the level of the selenoprotein was re-
duced substantially in a malignant prostate cell line and
in hepatocarcinoma. The expression pattern of the 15-
kDa protein in normal and malignant tissues, the occur-
rence of polymorphisms associated with protein expres-
sion, the role of selenium in differential regulation of
polymorphisms, and the chromosomal location of the
gene may be relevant to a role of this protein in cancer.
The essential trace element selenium occurs in several pro-
teins found in bacteria (1), archaea (2), and eukaryotes (1, 3).
All of the known selenoproteins described to date incorporate
selenium into protein co-translationally as the amino acid sel-
enocysteine (Sec)1 in response to the UGA codon (1, 3, 4), with
the exception of several bacterial molybdenum-containing en-
zymes such as Clostridium barkeri nicotinic acid hydroxylase
that contains an active center dissociable selenium species
(5–7). Among the selenoproteins thus far identified in mam-
mals are four glutathione peroxidases, three thioredoxin reduc-
tases, three thyroid hormone deiodinases, selenophosphate
synthetase, selenoprotein P, selenoprotein W, selenoprotein T,
selenoprotein R (also called selenoprotein X), selenoprotein N,
and a 15-kDa selenoprotein (1, 3, 8–10).
The 15-kDa selenoprotein was initially identified as a
strongly labeled protein that was detected when human T cells
were grown in the presence of [75Se]selenite (11). The open
reading frame within the human 15-kDa protein cDNA coded
for 162 residues and contained an in-frame TGA codon that
would result in the incorporation of Sec at codon position 93. A
putative stem-loop structure, designated the Sec insertion se-
quence (SECIS) element, was predicted in the 39-untranslated
region (39-UTR). SECIS elements are required for insertion of
Sec into protein at in-frame TGA codons and are located in the
39-UTR of higher eukaryotic selenoprotein mRNAs and imme-
diately downstream of the UGA Sec codon in bacterial seleno-
protein mRNAs (12). The 15-kDa protein did not have homol-
ogy to previously characterized proteins, but homologous
sequences were detected in other mammals as well as in the
nematodes Caenorhabditis elegans and Brugia malayi (11).
Nutritional levels of selenium have been inversely correlated
to the incidence of both prostate and lung cancer in human
epidemiological studies (13, 14). In addition, recent supplemen-
tation trials suggest that selenium may be effective in the
reduction of common human cancers, including those of the
prostate, colon and lung (15). Given the presence of selenium in
human proteins (1, 3), the absolute developmental requirement
for selenoprotein synthesis (16), and that selenium availability
at nutritional levels can influence selenoprotein levels (17), it is
probable that the chemopreventive properties of this element
are mediated through its role in one or more selenoproteins.
However, none of the identified selenoproteins have conclu-
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sively been linked to either the prevention or susceptibility to
any human cancers. As a first step in evaluating the biological
role of the newly discovered 15-kDa selenoprotein and its pos-
sible involvement as a chemopreventive agent in cancer, we
have characterized the 15-kDa protein gene in humans and the
corresponding cDNA sequence in mice. This analysis revealed a
polymorphism in the human SECIS element that influences
the level of 15-kDa protein synthesis. In addition, the 15-kDa
protein was found to be expressed in high levels in organs that
are protected from malignancy by selenium and in reduced
levels in the corresponding cancerous organs. These studies,
along with the observation that the 15-kDa protein gene maps
at a chromosomal location often associated with malignancy
(18, 19), raise the possibility that selenium may protect against
cancer, at least in part, through its influence on this protein.
EXPERIMENTAL PROCEDURES
Materials—Human liver mRNA was obtained from Invitrogen,
mouse cDNA clones from Genome Systems, and total RNA from human
tissues (human brain, pooled from two male Caucasians, ages 43 and
47; human heart, pooled from eight male/female Caucasians, ages 25–
73; human kidney, pooled from eight male/female Caucasians, ages
25–55; human liver, pooled from one male and one female Caucasian,
ages 35 and 15; human lung, pooled from five male/female Caucasians,
ages 14–40; human trachea, pooled from 84 male/female Caucasians,
ages 19–65; human mammary gland, pooled from eight female Cauca-
sians, ages 16–45; human prostate, pooled from 23 male Caucasians,
ages 23–64; human skeletal muscle, pooled from 10 male/female Cau-
casians, ages 23–56 (muscle of thigh, ileopsoas, and pectoralis major);
human testis, pooled from 19 male Caucasians, ages 17–61; and human
uterus, pooled from 10 female Caucasians, ages 15–77) and mouse
multiple tissue mRNA blots from CLONTECH. The mouse prostate
adenocarcinoma cell line Pr-14 (20) was kindly provided by Cheryl
Jorcyk and Jeffrey Green (National Institutes of Health). Normal and
malignant livers from transforming growth factor a (TGFa)/c-myc
transgenic mice (21) were obtained as described previously (22). Immu-
noblot reagents SuperSignal and ECL were obtained from Pierce and
Amersham Pharmacia Biotech, respectively, pET-21b(1) vector from
Novagen, the QuickChange site-directed mutagenesis kit from Strat-
agene, Lipofectin Reagent from Life Technologies, Inc., the Ni21-nitrilo-
triacetic acid column from Qiagen, the TSK-gel Phenyl 5-PW column
from TosoHaas, and the Mono-Q column from Amersham Pharmacia
Biotech. Avian myeloblastosis virus reverse transcriptase, Reporter
Lysis Buffer, and luciferase and b-galactosidase activity assay systems
were obtained from Promega. ThermoFidelase I was from Fidelity Sys-
tems. All other reagents were of the highest grade available.
Human Genomic DNA Sequencing—The human cDNA for the 15-
kDa protein (11) was used as a probe to search, in a hybridization
screen, for a genomic DNA clone in human BAC and PAC libraries from
Genome Systems. One ;100-kb clone hybridized with the probe, and
the 15-kDa protein gene present in the clone was sequenced using a
primer walking strategy. Sequencing was achieved without subcloning
using a recently developed procedure for direct sequencing of BAC
templates employing ThermoFidelase I (23). The addition of ThermoFi-
delase I into the cycle sequencing reaction allowed reading through
G/C-rich regions and prevented the stuttering of DNA polymerase on
single nucleotide repeats. A contiguous 64-kb genomic DNA sequence
was generated that contained the 51-kb 15-kDa selenoprotein gene,
except that approximately half of intron 2 was taken from a partial
sequence of a BAC clone generated by the Human Genome Project
(accession number HSDJ604K5).
Transcription Start Site—Primer extension analysis to map the tran-
scription start site of the 15-kDa protein gene was performed according
to a previously developed procedure (24). A synthetic oligonucleotide
primer (59-GCCAACAACAACCGTAGC-39) complementary to the 59-
end of the open reading frame (196/179 from the initiation codon) of
the selenoprotein gene was 59-labeled with [a-32P]ATP and hybridized
to 0.5 mg of human liver mRNA. The resulting complex was then reverse
transcribed using avian myeloblastosis virus reverse transcriptase. Ex-
tension products were electrophoresed on an 8% denaturing polyacryl-
amide gel and visualized by a PhosphorImager.
Mouse cDNA Sequence—Sequences of two mouse cDNA clones (ac-
cession numbers for EST clones are AA69039 and W71333) homologous
to the human 15-kDa protein sequence were determined using a Dye
Terminator Cycle Sequencing kit from PerkinElmer Life Sciences.
Northern and Southern Blot Analyses—Northern blot analyses using
the mouse cDNA probe for detecting the 15-kDa protein mRNA were
performed on a membrane from CLONTECH. Northern blot analyses to
detect the human 15-kDa protein mRNA were performed by running
total human RNA on a formaldehyde agarose gel, transferring it onto a
Nylon membrane, and hybridizing with a human cDNA as a probe.
Southern blot analyses using the human 15-kDa protein cDNA as
probe, and hybridization assays were performed as described (24). A
blot containing mRNA isolated from mouse testis following sucrose
gradient fractionation of polysomal and nonpolysomal RNA and subse-
quent isolation of RNA from each fraction was prepared as described
(25).
Immunoblot Analyses—Rabbit polyclonal antibodies that were raised
against the C-terminal peptide in the human 15-kDa protein (11) were
used for detection of the selenoprotein in mouse protein extracts. Se-
quencing of the mouse cDNA revealed that mouse and human seleno-
proteins had identical C-terminal amino acid sequences. SuperSignal
and ECL systems were used for signal detection. The isolated human
15-kDa protein was obtained as described (11) and used as a control for
immunoblot assays. The mouse prostate adenocarcinoma cell line Pr-14
was grown as described previously (20). Extracts of malignant and
matching normal livers from male TGFa/c-myc double-transgenic mice
were prepared as described (22) from either the same or different
animals as indicated. These mice, generated in a CD1xB6CBA F1
background, overexpress TGFa and oncogene c-myc, and represent a
well characterized in vivo model of accelerated hepatocarcinogenesis
(21). Male TGFa/c-myc mice develop easily identifiable liver tumors at
the age of 6–10 months.
Generation of Constructs for Functional Analysis of a SECIS Element
in the Human 15-kDa Selenoprotein Gene—Oligonucleotide primers 59-
CCAAGCTTTAGGCGTTAATGAAGACTACACAG-39 and 59-CCGCGG-
CCGCTGTATGTATCTGATCCACACAA-39 complementary to cDNA
positions 1092–1112 and 1130–1150 of human 15-kDa selenoprotein
were designed with terminal HindIII and NotI sites, respectively. Prim-
ers were used to PCR-amplify the minimal SECIS element from the
C811/G1125 cDNA. Mutagenesis to generate the polymorphic variant
element that has A1125 in place of G1125 was carried out by amplification
of an internal mutagenic oligonucleotide 59-TTAATGAAGA CTACAC-
AGAA AACCTTTCTA AGGATTTGTG TGGATCAGATACA-39 contain-
ing the desired nucleotide changes in combination with the above wild-
type oligonucleotides encoding the terminal restriction sites. PCR
products were digested with the appropriate enzymes and subcloned
into the corresponding sites of G16-D10DH3 (26). Once subcloned, the
amplified regions were sequenced in their entirety.
Transient Transfections—Transient transfections were carried out in
human embryonic kidney (HEK 293) cells using the calcium phosphate
method of transfection as described previously (27). Three days prior to
transfection, HEK 293 cells were plated onto 60-mm culture dishes in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf
serum. Cells were transfected with 10 mg of the pUHD10-3-based ex-
pression plasmids and 4 mg of the pUHD15 plasmid (28), which encodes
a protein necessary for transcriptional activation of the pUHD10-3
promoter. To monitor transfection efficiencies, cells were co-transfected
with 3 mg of an expression vector containing the human growth hor-
mone cDNA under control of the hamster sarcoma virus thymidine
kinase promoter. Medium was changed 1 day following transfection.
Two days after transfection, cells were harvested, washed, and resus-
pended in 0.1 M potassium phosphate, pH 6.9, containing 1 mM EDTA
and 0.25 M sucrose.
Deiodinase Assays—Cells were harvested 48 h after transfection by
scraping and sonicated, and cell sonicates were assayed for 59-deiodi-
nase activity as described previously (27). Briefly, cells were harvested,
washed, and resuspended in 0.1 M potassium phosphate, pH 6.9, con-
taining 1 mM EDTA, 0.25 M sucrose, and 10 mM dithiothreitol. Cells
were then sonicated and assayed for the ability to 59-deiodinate 125I
reverse T3. Reactions contained 10–250 mg of protein, 1 mM 125I reverse
T3, and 10 mM dithiothreitol in a reaction volume of 300 ml. Reactions
were incubated at 37 °C for 30 min. 125I release was quantitated as
described previously (27). Deiodinase activities were calculated per
microliter of cell sonicate and normalized to the amount of growth
hormone secreted into the medium. All constructs were tested in at
least three separate transfections, and deiodinase assays were per-
formed in duplicate from each transfection.
Reporter Constructs and Analysis—Reporter constructs designed to
evaluate SECIS element function were generated using human DNAs
for which the nucleotide positions at 811 and 1125 of the 15-kDa 39-UTR
were determined by PCR amplification and diagnostic restriction en-
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zyme digestion.2 A 533-nucleotide PCR amplification product contain-
ing the SECIS element was generated using human DNA as a template
and primers including the restriction endonuclease recognition se-
quence for either SpeI (59-AAAACTAGTGCTTTGTAACAGACTTGCG-
GTTAATTATGC-39) or PstI (59-AAACTGCAGGGTCTTACAAATGAT-
CACTTTTAAATGGAC-39). PCR products were cleaved with those
enzymes and directionally inserted into the polycloning site of the
pBPLUGA vector (30). The reporter construct was co-transfected into
mouse fibroblasts (NIH 3T3) with the pSV2neo plasmid at a 10:1 molar
ratio using the Lipofectin reagent. Lysates were generated by a single
freeze-thaw cycle following suspension in Reporter Lysis Buffer, and
luciferase and b-galactosidase activities were determined using the
corresponding assay systems. Luciferase activity was quantified using
a Fentomaster FB12 Luminometer from Zylux. For selenium supple-
mentation conditions, the cells were incubated at the indicated concen-
tration of sodium selenite for 5 days prior to lysis.
Computer Search Analyses—Protein and DNA homology analyses
were performed with BLAST programs (31). Putative structures for
human and mouse 15-kDa protein mRNAs were predicted with mfold
(32) and SECISearch (9) programs. The presence of N-terminal signal
peptides was determined with sequence analysis programs SignalP and
PSORT II.
RESULTS
Sequence and Structural Organization of the Human 15-kDa
Protein Gene—A human BAC library was screened with a
radioactive probe representing the human 15-kDa protein
cDNA resulting in the isolation of a positively hybridizing
clone. Restriction enzyme analysis of this clone by Southern
blotting indicated that a variety of infrequent cutting restric-
tion endonucleases used separately to digest the BAC insert
resulted in several 15-kDa protein cDNA-hybridizing frag-
ments (data not shown). This suggested that the 15-kDa sel-
enoprotein gene was relatively large and constituted a signifi-
cant portion of the BAC clone. A recently developed technique
of direct sequencing of large genomic DNA clones using a
ThermoFidelase system was then utilized to determine the
insert sequence using primers designed from the selenoprotein
cDNA sequence followed by a primer walking strategy to de-
termine intron sequences.
The structural organization of the human 15-kDa protein
gene is shown in Fig. 1 and Table I. By comparison of the
obtained gene sequence and the previously reported cDNA
sequence, the gene for the 15-kDa protein was established to be
51 kb long and consisted of five exons and four introns (Table I).
All exon-intron junctions contained the consensus AG/GT se-
quences that typically flank splice junctions (Table I). Com-
puter search analysis of the determined gene sequence against
dbESTs identified several positional markers supporting the
previous determination that the gene for the 15-kDa protein is
located on chromosome 1 at position 1p31 (data not shown).
The first exon in the selenoprotein gene included the 59-UTR
as well as the first 27 amino acid residues corresponding to a
putative signal peptide. This N-terminal peptide, while pre-
dicted from the gene sequence, was absent in the isolated
human T-cell 15-kDa selenoprotein as evidenced by direct de-
termination of the mass of the isolated selenoprotein and by
direct sequencing of the tryptic peptides derived from the 15-
kDa protein (11). The coding of an N-terminal signal peptide by
a unique exon is often seen for other mammalian proteins. The
TGA codon that encodes Sec was located in exon 3, while the
largest exon, exon 5, contained the C-terminal coding region
and the complete 39-UTR.
In addition, we determined 6.8 kb in the 59-flanking and 6.0
kb 39-flanking regions for the human 15-kDa protein gene. The
first 477 nucleotides of the gene for heparan sulfate 2-sulfo-
transferase (accession number AB007917) were detected in the
reverse orientation upstream of the selenoprotein gene within
nucleotides 5741–6217 of the BAC clone. The downstream
neighbor of the 15-kDa selenoprotein gene could not be
identified.
A computer search analyses for sequences homologous to the
human 15-kDa protein detected a previously deposited se-
quence on human chromosome 7q31–3q32 (82% identity to the
15-kDa protein cDNA sequence in a 125-nucleotide overlap;
accession number AC004925). This sequence lacked introns
and was characterized by in-frame stop signals, suggesting
that it represented a 15-kDa protein pseudogene that probably
arose by reintegration of a cDNA copy of the 15-kDa protein
mRNA.
In order to establish the site of transcription initiation,
primer extension of an oligonucleotide that complemented the
region encoding the N-terminal portion of the coding region
(196/179 from the initiation codon) was utilized. The primer
was extended up to 20 bases beyond the point corresponding to
the bases of the open reading frame (Fig. 2). The nucleotide at
the initiation site was adenylic acid. The gene did not contain a
canonical TATA box consensus sequence about 30 base pairs
upstream of the transcription initiation site as is common
among many polymerase II transcribed genes. The sequence at
the initiation site, AGAAACC (where A designates the tran-
scription start point) is similar to the approximate consensus
sequence reported for mammalian polymerase II-transcribed
genes that initiate transcription with or without an upstream
TATA box (33). The approximate consensus sequence was de-
termined to be YYA11N(T/A)YY. Clearly, the nucleotide at the
transcription start point for the 15-kDa protein gene and those
nucleotides downstream fit the consensus sequence, while the
two purines upstream do not conform.
Analyses of Human EST Sequences—The human 15-kDa
protein cDNA was represented in dbEST by more than 200
independent EST sequences. Based on these available se-
quence data, it was apparent that exon 4, predicted to consist of
50 nucleotides, was missing in ;7.5% of the ESTs (3 out of 42).
A transcript lacking exon 4 would be slightly shorter (149
residues in length) and would presumably be a nonfunctional
polypeptide. Interestingly, if this alternative splicing was to
2 Y. J. Hu, K. V. Korotkov, R. Mehta, D. L. Hatfield, C. Rotimi, A.
Luke, T. E. Prewitt, R. S. Cooper, W. Stock, E. E. Vokes, M. E. Dolan,
V. N. Gladyshev, and A. M. Diamond, manuscript in preparation.
FIG. 1. Structural organization of the human 15-kDa seleno-
protein gene. A, the exon-intron organization and the size of exons
and introns in the selenoprotein gene predicted by sequence analysis
are shown. Open squares correspond to introns and flanking regions,
and the closed squares correspond to exons. The sizes of introns and
flanking regions are indicated. B, the organization of the human cDNA
sequence and the relative positions of the ATG initiation and the TGA
Sec codons, the TAA termination signal, and the detected polymor-
phisms (C811/T811 in the SECIS-like structure and G1125/A1125 in the
SECIS element) are shown. Alternative 39-end sequences (position 1244
or 1519 within the cDNA) of exon 5 are also indicated. The long hori-
zontal line corresponds to the 15-kDa protein cDNA, and short vertical
lines correspond to exon-exon junctions. Numbers under junction sites
correspond to the last nucleotides in the preceding exons. bp, base pairs.
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occur in the human 15-kDa protein gene, two in-frame TGA
codons downstream of the TGA Sec codon would be present.
Translation of this transcript would yield a protein containing
three Sec residues. Determining whether such a polypeptide is
indeed expressed in human cells will require further studies.
However, in preliminary experiments we could not detect DNA
sequences lacking exon 4 when total human brain, kidney,
liver, heart, and lung RNAs were amplified by reverse tran-
scriptase-PCR with primers corresponding to exons 3 and 5,
followed by sequencing of PCR products. In contrast, the se-
quence containing exon 4 was observed by this method (data
not shown).
The presence of a SECIS element in the 39-UTR of eukaryotic
selenoprotein genes is necessary and sufficient to decode in-
frame TGA codons as Sec (12). The human 15-kDa protein gene
has a single functional SECIS element (see below). Unlike this
and other known mammalian selenoprotein genes that encode
a single Sec residue and contain a single SECIS element, the
selenoprotein P gene encodes 10–12 Sec residues and contains
two distinct SECIS elements (34). It is not known if a single
SECIS element in a mammalian selenoprotein gene is suffi-
cient to incorporate multiple Sec residues, such as those that
may appear in the 15-kDa selenoprotein derived from an alter-
native transcript lacking the fourth exon.
Two polymorphic sites (nucleotide positions 811 and 1125 in
the human cDNA) located in the 39-UTR were previously pre-
dicted in the 15-kDa protein gene from an analysis of the EST
data base (11). We have expanded on this initial analysis to
include currently available human EST sequences. The analy-
sis indicated that C811 nucleotide was associated with G1125,
while T811 was associated with A1125 in every EST sequence
that contained both polymorphic sites, suggesting the presence
of only two alleles, C811/G1125 and T811/A1125. We found that at
position 811 in the cDNA sequence, T occurred 19 times, while
C was present in 32 ESTs. Likewise, A at position 1125 oc-
curred in 37 sequences, while G occurred in 89 sequences at
this position. This transforms into ;32%/68% frequency distri-
bution of T811/A1125 and C811/G1125 alleles in the submitted
sequences. No sex, tissue, or age differences in distribution
were found between the two polymorphic forms of the gene
based on the EST analysis.
It was also observed that 20 out of 141 EST sequences that
corresponded to the 39-end of the human 15-kDa protein gene
were extended beyond previously reported sequences for an
additional 275 nucleotides. Examination of extended sequences
revealed that they originated from a direct continuation of exon
5 due to an alternative distal atypical poly(A) site usage. The
extended sequences showed no homology to previously charac-
terized sequences and contained no SECIS-like structures. The
complete cDNA sequence corresponding to the longer tran-
script and containing C811/G1125 polymorphisms has been de-
termined by sequencing an EST clone (accession number
AA001402).
SECIS Element Functional Studies—In the human 15-kDa
protein cDNA sequence, the G1125/A1125 polymorphic site is
located in the apical loop of the putative SECIS element (Fig.
3). To determine if this stem-loop structure was indeed in-
volved in Sec incorporation, we utilized a thyroid hormone
deiodinase system previously used extensively to determine the
efficiency of wild type and mutant SECIS elements in mamma-
lian selenoproteins (27). A construct was made in which the
putative SECIS element from the 15-kDa selenoprotein gene
replaced the SECIS element in the deiodinase gene. As a pos-
itive control for SECIS function, the deiodinase gene containing
the wild type SECIS element was used. Transfection of these
constructs into human embryonic kidney 293 cells showed that
the SECIS element in the 15-kDa protein gene was functional
and that its efficiency of Sec incorporation was approximately
one-half of that of the deiodinase natural SECIS element (Fig.
4). However, replacement of G1125 with an A in the apical loop
of the SECIS element increased incorporation of Sec into deio-
FIG. 2. Identification of the transcription start site by primer
extension analysis. The analysis was carried out using a 32P-labeled
synthetic oligonucleotide primer as described under “Experimental Pro-
cedures.” Primer extension product is marked as EP. Underlined A
indicates the transcription start site, and the arrow pointing to the
right indicates the direction of transcription. Coding sequences are
shown in boldface type, and the primer is indicated by the arrow
pointing to the left.
TABLE I
Organization of the 15-kDa protein gene
Exon (size, bp) Coding information Intron (size, bp) Splice donor Splice acceptor
1 (97) 59-UTR 1 coding region for
signal peptide
1 (10,610) AAGCGgtgag ttcagGTGTC
2 (168) Coding region 2 (22,561) AAAAGgtact tgtagCTGTA
3 (64) Coding region
(selenocysteine)
3 (12,537) CCAAGgtata ataagCTTTT
4 (50) Coding region 4 (4446) TCAAGgtaag tgtagTATGT
5 (.883) Coding region 1 39-UTR
Exon sequences are shown in uppercase and intron sequences in lowercase. bp, base pairs.
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dinase to about 75% of that observed in the wild type construct.
Thus, G1125 seems to be a less active template for Sec insertion
into a nascent selenopeptide when the growth medium was not
supplemented with selenium (Fig. 4).
Further computer analysis of the human selenoprotein gene
revealed the presence of an additional SECIS-like structure
(Fig. 3). This structure satisfied criteria for both the primary
sequence and secondary structure of the SECIS element, al-
though the free energy for this structure was not as low as in
most known human SECIS elements, and the structure could
not be found with SECISearch (9). Nevertheless, this structure
was thermodynamically similar to the SECIS elements in the
human selenoprotein P gene, suggesting that it may potentially
be a functional unit. Interestingly, the second polymorphic site
found in the human selenoprotein gene, C811/T811, was located
in this second SECIS-like structure (Fig. 3).
A possible role of the SECIS-like element and the C811/T811
polymorphic site located in the internal loop of this structure in
inserting Sec into a protein was tested by making a construct
that contained this stem-loop structure in place of a wild-type
SECIS element in the deiodinase gene. Transfection of either
C811 or T811 form of this construct into HEK 293 cells revealed
that the SECIS-like structure was not functional (data not
shown). Thus, the human 15-kDa protein gene apparently has
only one functional SECIS element.
Functional Consequences of the Polymorphic Sequences Lo-
cated in the 15-kDa Protein SECIS Elements—Having deter-
mined that the G1125/A1125 polymorphic site resided in the
sequence capable of functioning as a SECIS element and that
the identity of the 1125 nucleotide influenced the amount of
deiodinase activity in the transfected cells, we next evaluated
this phenomenon in greater detail. To quantitatively measure
SECIS function, we utilized a reporter plasmid specifically
designed to measure the ability of inserted sequences to pro-
mote the read-through of a UGA codon strategically placed
between the genes for b-galactosidase and luciferase (30).
Transient transfection of this plasmid resulted in detectable
b-galactosidase in extracts prepared from transfected tissue
culture cells. If a functional SECIS sequence was inserted in
the polycloning region of the 39-UTR, then translation of the
UGA resulted in read-through into the luciferase gene and
detectable activity in the prepared extracts. The ratio of lucif-
erase to b-galactosidase activities was therefore a measure of
SECIS efficiency of the inserted sequence normalized to the
transfection efficiency as indicated by the b-galactosidase
levels.
Segments of DNA spanning the 15-kDa protein SECIS se-
quence representing either the T811/A1125 and C811/G1125 hap-
lotype were generated by PCR, cloned into the pBPLUGA
reporter plasmid, and transfected along with the pSV2neo
into NIH 3T3 mouse fibroblasts. Extracts prepared from
pBPLUGA-CG or pBpLUGA-TA plasmids yielded significant
luciferase and b-galactosidase activities, while the parental
pBPLUGA plasmid yielded only b-galactosidase activity. Con-
sistent with the deiodinase assays (Fig. 4), the luciferase activ-
ity was higher for pBPLUGA-AT transfected cells compared
with those containing pBpLUGA-CG (data not shown).2 The
tissue culture medium used for mammalian cells is generally
regarded as being selenium-deficient as compared with human
serum. We therefore determined whether there was a differ-
ence in SECIS function between the two plasmids as a function
of increasing selenium concentration. As seen in Fig. 5, where
the luciferase activity is normalized to base-line levels observed
in unsupplemented medium, the reporter construct containing
C811/G1125 showed a greater response to added selenium than
did that containing T811/A1125. These results collectively dem-
onstrate that the identity of the nucleotides at 811/1125 influ-
ence the function of the 15-kDa protein SECIS element in a
selenium-dependent manner.
cDNA for the Mouse 15-kDa Selenoprotein—Given the above
described allelic variation in the 15-kDa gene in humans, we
searched for similar genetic diversity in mice. We initially
determined nucleotide sequences of mouse EST clones that
were homologous to the human 15-kDa selenoprotein gene.
Examination of these sequences indicated that the mouse
cDNA sequence potentially encoded a protein of 162 residues.
An N-terminal signal peptide spanning residues 1–27 of the
mouse 15-kDa selenoprotein was predicted with sequence anal-
ysis programs. The mouse protein predicted by cDNA se-
quences was highly homologous to the human protein, and the
mature proteins would differ by only 5 residues (Fig. 6). Like-
wise, the rat 15-kDa protein sequence, obtained by multiple
sequence alignments of rat 15-kDa protein EST sequences,
FIG. 4. Incorporation of Sec into thyroid hormone deiodinase
1 with the 15-kDa protein SECIS element. Constructs were pre-
pared and assayed as described under “Experimental Procedures.”
G1125 and A1125 are two natural polymorphic forms of the 15-kDa
protein SECIS element that were used to test Sec incorporation into
thyroid hormone deiodinase. D1 indicates a control assay that utilized
the thyroid hormone deiodinase 1 natural SECIS element. The data
shown are the result of three independent measurements.
FIG. 3. SECIS element structures in the 3*-UTR of the human
15-kDa selenoprotein gene. A, the SECIS-like structure located at
positions 754–819 is shown. This structure contains the C811/T811 poly-
morphism in the internal loop and was found not to be functional. B, the
sequence of the SECIS element located at positions 1090–1154 is
shown. This structure contains the A1125/G1125 polymorphism in the
ministem of the apical loop and was found to be functional (see Figs. 4
and 5). The non-Watson-Crick Quartet sequence and a preceding A are
boxed, and the conserved AA motif in the apical loop is circled.
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differed from the human counterpart by 3 residues and the
mouse by 2. The greatest conservation of gene sequence was
present within the last 96 residues, which were identical in all
three mammalian proteins, while all sequence variations oc-
curred in the N-terminal portions of proteins.
The mouse 15-kDa protein gene was represented in dbEST
by more than 100 sequences. As was observed in the human
gene, analysis of these sequences suggested the presence of two
major polymorphic forms corresponding to two alleles. These
differed by at least 5 nucleotides (form 1: C323, T438, G681, A1166,
and T1275; form 2: T323, C438, A681, G1166, and G1275). The first
three nucleotide variations were located in the coding region,
and the last two were in the 39-UTR. Polymorphisms at nucle-
otides 438 and 681 did not result in changes in selenoprotein
amino acid sequence, while substitution of nucleotide 323 re-
sulted in a change from alanine to valine at position 26 in the
protein sequence. None of the polymorphic positions were lo-
cated in a single predicted SECIS element identified in the
mouse sequence, and the closest polymorphic site to that ele-
ment was located 10 nucleotides upstream. Form 1 was 4 times
more abundant than form 2 among mouse EST sequences, and
it was present in at least eight different mouse strains. Form 2
was present exclusively in the Barstead colon library (strain
FVB/N) and in the Soares mammary gland NbMMG library
(strain C57BL/6J). Further analysis of these two strains re-
vealed that previously sequenced ESTs generated from the
FVB/N strain included only form 2, while those sequences
reported from the C57BL/6J strain contained both forms of the
selenoprotein gene.
Expression and Translation of 15-kDa Protein
mRNAs—Northern blot analysis of the human 15-kDa protein
mRNA is shown in Fig. 7. The 1.3-kb human selenoprotein
mRNA was expressed in high levels in prostate, liver, brain,
kidney, and testis, while it was essentially undetectable in
muscle, mammary gland, and trachea. Several human tissues
also exhibited an additional 15-kDa protein mRNA band of 1.6
kb that was present in minor levels in tissues such as lung,
prostate, and uterus but present in major levels in testis. This
band corresponds to an extended human 15-kDa protein cDNA
sequence (containing a 275-nucleotide extension of exon 5) as
observed in a portion of human EST sequences (see above).
The levels of expression of the mouse 15-kDa protein mRNA
were assessed by Northern blot analysis as shown in Fig. 8 and
corresponded to the expression pattern observed for the human
15-kDa protein mRNA (Fig. 8). As expected, the size of the
mouse 15-kDa protein mRNA was ;1.4 kb in all tissues exam-
ined except testis, where the analysis indicated two hybridizing
bands, one of ;1.4 kb and another of ;1.7 kb (Fig. 8).
To assess the contribution of the 1.4- and 1.7-kb mRNAs to
15-kDa protein synthesis, a blot prepared with mRNA isolated
from polysomal and nonpolysomal fractions from mouse testis
was hybridized with the appropriate cDNA probe. Interest-
ingly, the nonpolysomal fraction contained approximately
equal amounts of both mRNA forms, while the polysomal frac-
tion contained greater than 90% of the 1.4-kb mRNA (data not
shown).
Expression of the Mouse 15-kDa Selenoprotein—Levels of the
15-kDa protein were examined in several mouse tissues and
cells by Western blot analyses. Isolated native human protein
was used as a standard to determine the size of the 15-kDa
protein detected with our antibodies in mammalian cells. The
data suggest that the major form of the protein in mouse cells
was the form lacking the N-terminal signal peptide, since the
FIG. 5. Effect of nucleotide identities at positions 811 and 1125
on SECIS function. NIH 3T3 cells transfected with either pB-
PLUGA-CG () or pBpLUGA-TA plasmids (30), containing the poly-
morphic sequences C811/G1125 and T811/A1125, respectively, were cul-
tured for 5 days in the indicated amount of selenium, after which cells
were harvested and lysates were generated for the analysis of luciferase
and b-galactosidase activities. The luciferase activity was normalized
by dividing by the measured b-galactosidase activity, and the data
presented in the figure represent the percentage increase over base-line
luciferase/b-galactosidase obtained from cultures without added sele-
nium. The data are the average of the analysis of at least three inde-
pendent cultures, and the error bars represent the S.E.
FIG. 6. Homology among human, mouse, and rat 15-kDa pro-
teins. The human sequence, previously determined (Ref. 11; accession
number NM004261), the mouse sequence determined herein, and the
rat sequence derived from multiple alignments of rat EST sequences
are compared. Mouse and rat residues that are different from the
human 15-kDa protein sequence are highlighted. Sec residues (shown
as U) in all three sequences and a variant amino acid residue 26 in the
mouse sequence are shown as boxes.
FIG. 7. Northern blot analysis of human 15-kDa protein mRNA.
Expression of the 15-kDa protein mRNA was examined by Northern
blot analysis in various tissues as shown. The blot was hybridized with
the human cDNA probe (shown in A), stripped, and then hybridized
with b-actin probe (shown in B).
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detected mouse protein migrated similarly to the 15-kDa pro-
tein standards that lacked the N-terminal sequence.
Altered expression of the 15-kDa protein may be significant
in the etiology of tumor development and/or the mechanism by
which selenium functions in cancer prevention. The above de-
scribed Western analysis indicated relatively high levels of
expression in both the prostate and liver, two organs previously
indicated as being responsive to the chemopreventive effects of
selenium (13–15). Previously, we have examined selenoprotein
levels in transgenic TGFa/c-myc mice (22), which is a mouse
model for accelerated hepatocarcinogenesis (21). In that study
(22), it was found that GPx1 levels were significantly decreased
in liver tumors compared with surrounding liver tissue,
whereas levels of another major selenoprotein, TR1, were
slightly elevated. Using this model, levels of the 15-kDa sel-
enoprotein were assessed in liver tumors and adjacent tissue
by Western blotting. Two pairs of matched samples (from the
same animals) and individual tumor and normal livers (Fig.
9B) were analyzed, and in each case the levels of the 15-kDa
protein were lower in the tumors. In addition to the observed
difference in expression of the selenoprotein in hepatocarcino-
mas, the 15-kDa protein was not detectable in mouse prostate
adenocarcinoma cells, while normal mouse prostate showed a
strong signal with 15-kDa protein-specific antibodies (Fig. 9A).
DISCUSSION
The 15-kDa selenoprotein is among the more recently dis-
covered proteins shown to contain the Sec amino acid encoded
by an in-frame UGA codon (11). Previously, only the cDNA
sequence obtained from characterization of a human EST clone
was available. In this work, the organization and sequence of
the gene for this protein were determined from human genomic
DNA. The human gene spans 51 kb and is organized in five
exons and four introns with the Sec-encoding TGA codon in
exon 3 and a SECIS element in exon 5. The human 15-kDa
selenoprotein gene was located on chromosome 1 at position
p31. This region is commonly mutated or deleted in human
cancers, and the presence of a tumor suppressor gene on 1p31
has been suggested (18, 19). The loss of one copy of the 15-kDa
protein gene may result in the decrease in selenoprotein ex-
pression in malignant tissues relative to the corresponding
normal tissue.
Analyses of publicly available cDNA sequences derived from
the 15-kDa protein gene revealed two single nucleotide poly-
morphisms at positions 811 and 1125 in the human cDNA.
These were organized into two alleles, C811/G1125 and T811/
A1125 in the 68%/32% frequency distribution. Only these two
haplotypes were observed in cDNA sequences submitted to
date and this is also the case in over 700 human DNA samples
examined.2
The human 15-kDa protein gene gives rise to several mRNA
forms. The major mRNA form has been previously described
(11), and we now detected additional human mRNA forms that
lack exon 4 or contain extended exon 5. We found that exon 1
encodes an N-terminal signal peptide spanning amino acid
residues 1–27 of the human sequence that is also present in
rodent sequences, suggesting that the mammalian 15-kDa pro-
tein is a compartmentalized protein. This conclusion is sup-
ported by the observation that N-terminal amino acid residues
are not present in the isolated human 15-kDa protein (11).
Previously, the presence of the SECIS element in the 39-UTR
of the human 15-kDa protein gene was predicted by structural
similarity to other selenoprotein genes. In this work, we estab-
lished that this element was indeed functional by demonstrat-
ing that it could replace the natural SECIS element of the
thyroid hormone deiodinase 1 gene with comparable efficiency.
Furthermore, these sequences were able to support the read-
through of an in-frame UGA codon separating the b-galacto-
sidase and luciferase genes in a reporter construct specifically
designed for this purpose.
Since the 1125 polymorphic site was located in the apical
loop of a functional SECIS element, we tested the hypothesis
that the identity of the nucleotide at this position may influ-
FIG. 8. Northern blot analysis of mouse 15-kDa protein mRNA.
Expression of the 15-kDa protein mRNA was examined by Northern
blot analysis in various tissues as shown. The blot was hybridized with
the mouse cDNA probe (shown in A), stripped, and then hybridized with
b-actin probe (shown in B).
FIG. 9. Immunoblot detection of the mouse 15-kDa selenopro-
tein in tumors and normal tissues. Expression of the 15-kDa protein
was examined in various normal and malignant cells and tissues by
Western analysis as shown. A, lane 1, liver of TGFa/c-myc transgenic
mouse (10 months); lane 2, liver tumor of TGFa/c-myc mouse (from the
mouse as in lane 1); lanes 3 and 7, mouse prostate (wild type); lanes 4
and 10, purified 15-kDa selenoprotein from human T cell line JPX9;
lanes 5 and 6, mouse prostate adenocarcinoma cell line Pr-14 (20); lane
8, liver of TGFa/c-myc mouse (10 months); lane 9, tumor liver of TGFa/
c-myc mouse (from the same mouse as in lane 8). B, lanes 1 and 2, liver
of wild type mice (2.5 months); lanes 3 and 4, liver of TGFa/c-myc mouse
(2.5 months); lanes 5 and 6, liver of TGFa/c-myc mouse (2.5 months);
lanes 7 and 8, liver of TGFa/c-myc mouse (10 months); lanes 9–11, liver
tumors of TGFa/c-myc mouse (10 months); lanes 12 and 13, liver of wild
type mouse (1 month); lanes 14 and 15, liver of TGFa/c-myc mouse (1
month); lanes 16 and 17, liver of TGFa/c-myc mouse (1 month); lanes 18
and 19, liver of TGFa/c-myc mouse (10 months); lanes 20–22, liver
tumors of TGFa/c-myc mouse (10 months). All samples were obtained
from different mice. Equal protein amounts were loaded on each lane.
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ence Sec incorporation. We initially found that A1125 was more
efficient than G1125 in supporting synthesis of active thyroid
hormone deiodinase. In this experiment, the growth medium
was supplemented with 10% fetal calf serum, which may be
considered as a modest selenium deficiency, since serum is the
major source of selenium for protein synthesis under cell cul-
ture conditions and the level of selenium in 10% fetal calf
serum-supplemented medium is low (29). We further extended
these observations by employing a b-galactosidase-UGA codon-
luciferase-SECIS construct, in which the sequence spanning
both polymorphisms in the human 15-kDa selenoprotein gene
was included in the construct. Using transiently transfected
cells, we were able to detect differences in SECIS element
function between the two naturally occurring alleles (C811/
G1125 and T811/A1125) of the 15-kDa protein gene. The SECIS
elements from these two haplotypes differed in their activity in
medium unsupplemented with selenium and the same medium
supplemented with 30–90 nM sodium selenite (Fig. 5). This
finding was also supported by the analysis of stably transfected
cells and nonnatural polymorphic forms of the 15-kDa protein
gene.2
Thus, natural polymorphisms found in the 39-UTR of the
15-kDa protein gene influence expression levels of the seleno-
protein gene product, and this occurs in a selenium-dependent
manner. It is therefore possible that individuals representing
different combinations of these two haplotypes may express
different amounts of the 15-kDa selenoprotein and, in addition,
they may differentially respond to changes in dietary selenium
(i.e. differentially control expression levels of the 15-kDa pro-
tein in response to changes in selenium levels). The role of
natural polymorphisms in affecting Sec incorporation into a
selenoprotein and influencing selenoprotein levels as well as
the role of selenium in these processes have not been previously
described for any other selenoprotein.
In addition to the human selenoprotein gene, the existence of
two haplotypes was detected in the mouse 15-kDa protein cDNA
sequences. However, in the mouse, multiple sequence differences
between the two alleles were detected. At present the functional
consequences of these polymorphisms remain unknown. We also
detected two forms of the mouse 15-kDa protein mRNA, but in
contrast to a human gene, the longer form of mouse mRNA was
only expressed in testes. Although both forms were present in
equal amounts in mouse testes, the shorter one was predomi-
nantly associated with polysomes, suggesting that it is utilized in
protein synthesis to a far greater extent than the longer form.
Examination of the expression pattern of the 15-kDa protein
indicated that various tissues expressed very different levels of
both this protein and its mRNA.
It is noteworthy that prostate and liver in both humans and
mice express relatively high levels of the 15-kDa protein. Hu-
man selenium supplementation trials have suggested that di-
etary selenium can reduce cancer incidence in these two organs
(15), and it is likely that the most protection is provided to
those with lower selenium intake. Furthermore, epidemiologi-
cal data have indicated a statistically significant inverse cor-
relation between selenium in the diet and prostate cancer (13).
However, the mechanism of cancer prevention by selenium is
poorly characterized, and no selenoprotein has been implicated
in such protection. The data presented in this study raise the
possibility that the 15-kDa protein may function in the preven-
tion of cancer and possibly serve as an agent by which selenium
supplementation exerts its chemopreventive effect. Consistent
with this notion is our observation that liver tumors expressed
reduced levels of the 15-kDa protein compared with adjacent
hepatic tissue in the TGFa/c-myc mouse model used in this
study. In addition, 15-kDa selenoprotein levels were essentially
undetectable in a mouse prostate cancer cell line, while this
protein was abundant in a normal mouse prostate. If lower
levels of the 15-kDa protein predispose to malignant transfor-
mation, then the observation that the difference in SECIS
element function between the two naturally occurring alleles in
the human population may indicate a segment of the popula-
tion who are either at greater risk of cancer or might benefit
from selenium supplementation. The above observations and
the fact that the region of chromosomal location of the 15-kDa
protein gene is often associated, following deletion or mutation,
with malignancy suggest a possible role of the 15-kDa protein
in cancer etiology.
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